Indications
Haemorrhage
Somatostatin is indicated for:
Severe acute haemorrhage from oesophageal varices.
Severe acute haemorrhage from gastric or duodenal ulcers, or accompanying acute erosive or haemorrhagic gastritis.
Adjuvant treatment of pancreatic, biliary and intestinal fistulae.
... Read more
Somatostatin is indicated for:
Severe acute haemorrhage from oesophageal varices.
Severe acute haemorrhage from gastric or duodenal ulcers, or accompanying acute erosive or haemorrhagic gastritis.
Adjuvant treatment of pancreatic, biliary and intestinal fistulae.
Prophylaxis and treatment of postoperative complications following pancreatic surgery.
Dosage And Administration
Somatostatin is given intravenously, by slow bolus injection (3 to 5 minutes) of 250 µg or by continuous infusion at a rate of 250 µg/hour (equivalent of approximately 3.5 µg/kg body weight/hour). The lyophilised powder should be reconstituted with the physiological sodium chloride solution immediately prior to use. For continuous infusion one 3 mg of Somatostatin ampoule should be used to prepare a 12 hours infusion. The solution may be either saline or 5 % dextrose and should be adjusted to guarantee an outflow of 250 µg somatostatin/hour. The use of a perfusion syringe is recommended.
Treatment of severe acute bleeding from the upper gastro-intestinal tract, including from oesophageal varices: It is recommended to start by a slow intravenous injection of 250 µg of Somatostatin as loading dose, then immediately followed by an intravenous infusion at a rate of 250 µg/h. In case of interruption of more than 3 to 5 minutes between two infusions, an additional slow intravenous injection of 250 µg is recommended to ensure a continuous treatment. Once the haemorrhage has stopped (usually in less than 12 to 24 hours), treatment should be continued for 48-72 hours in order to avoid rebleeding. Treatment up to 120 hours has been routinely performed in this indication.
Adjuvant treatment in pancreatic, biliary and intestinal fistulae: A continuous infusion of Somatostatin at a rate of 250 µg/h is recommended until closure of the fistulae (2-20 days). This infusion should be performed in addition to total parenteral nutrition. Once the fistula has been closed, treatment should be continued for 1 to 3 days and stopped progressively in order to avoid rebound effect. Prophylactic treatment of postoperative complications following pancreatic surgery: Somatostatin is administered at the beginning of the surgical intervention at a rate of 250 µg/h and treatment is continued for 5 days.
Side Effects
Nausea, vertigo, and flushing have been reported rarely. Nausea and vomiting have been reported when the infusion rate is greater than 50 µg/min.
Precautions And Warnings
Due to its inhibitory effect on the secretion of insulin and glucagon, the administration of Somatostatin can, at the onset of treatment, lead to a transient fall in blood glucose level. Caution is, therefore, called for in insulin-dependent diabetic patients in whom blood glucose should be measured every 3-4 hours. Simultaneous administration of insulin-requiring sugars should, if possible, be avoided. If necessary, insulin should be administered.
Pregnancy And Lactation
Avoid in pregnancy unless there is no safer alternative.